Wearable devices can identify, differentiate, and predict flare-ups, or the worsening of symptoms and inflammation, in inflammatory bowel disease (IBD), Mount Sinai researchers have shown in a ...

Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...

Eating a Mediterranean-style diet can help people manage IBD symptoms, and a new cookbook from Crohn's & Colitis Ireland ...

The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely ...

The Crohn’s and Colitis Foundation’s 34th annual Torch Gala is set to take place on Saturday, Feb. 8 in Atlanta, with three ...

4 Sorbonne Universités—UPMC Univ Paris 06, INSERM ERL 1157, AP-HP, Hôpital Saint Antoine, CNRS UMR 7203 LBM, CHU Saint-Antoine, Paris, France Objectives Preventing postoperative recurrence after ...

Vedolizumab treatment within 4 weeks of ileocolonic resection outperformed placebo in preventing postoperative endoscopic recurrence of Crohn’s disease in patients with at least one risk factor ...

Since then, I think it’s fair to say that most people have been nervous about the emergence of the next big infectious disease – be that a virus, bacterium, fungus or parasite. With COVID in ...

Early treatment of pediatric Crohn's disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn's ...

Patients who receive treatment with risankizumab for Crohn disease (CD) are able to sustain clinical improvements in health-related quality of life (HRQOL) at 104 weeks, according to study results ...

A study by University of Michigan researchers may provide an explanation for why some patients with Crohn's disease continue to experience symptoms, even in the absence of inflammation. The ...